Advertisement

Product Characterization is a Journey

  • John Geigert
Chapter

Abstract

Product characterization is necessary to establish identity and consistency, and probably most important, patient safety, for any pharmaceutical, including a biopharmaceutical. But compared to chemical drugs, the biopharmaceuticals are large molecules (protein), or very large living particles (virus), or very very large living systems (cells). For a biopharmaceutical, product characterization includes the physical structures, the chemical properties, and in addition, the functional activities. Since there is so much that we can learn about these large molecules and there are so many test methods that we can use to study them, a risk-based approach is presented to determine what product characterization is necessary and when is that knowledge needed as the biopharmaceutical advances through clinical development from initial first-in-human studies to reaching market approval. In this chapter, the product characterization of three groups of biopharmaceuticals will be examined: (1) recombinant proteins and monoclonal antibodies, (2) genetically engineered viruses, and (3) genetically engineered cells.

Keywords

Primary structure Posttranslational Higher-Order Aggregation Disulfide bonding Deamidation Truncation Glycosylation Genomic Proteomic 

References

  1. 1.
    ICH Q6B Specifications: Test Procedures and Acceptance Criteria For Biotechnological/Biological Products (March 1999); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q6B/Step4/Q6B_Guideline.pdf
  2. 2.
    Kozlowski, S., and Swann P., Current and Future Issues in the Manufacturing and Development of Monoclonal Antibodies; Adv. Drug Deliv Rev. (2006) 58(5–6): 707–722CrossRefGoogle Scholar
  3. 3.
    Randhawa, Z. L., Witkowska, H. E., et. al, Incorporation of Norleucine at Methionine Positions in Recombinant Human Macrophage Colony Stimulating Factor (M-CSF, 4-153) Expressed in E. Coli: Structural Analysis; Biochemistry (1994) 33(14): 4352–4362CrossRefGoogle Scholar
  4. 4.
    Hedayati, M. H., Norouzian, D., et.al., Identification of Methionine Oxidation in Human Recombinant Erythropoietin by Mass Spectrometry: Comparative Isoform Distribution and Biological Activity Analysis; Prep. Biochem & Biotech (2017) 47(10): 990–997Google Scholar
  5. 5.
    FDA Advisory Committee Meetings – Meeting of the Arthritis Advisory Committee: Sandoz Erlezi (Etanercept, Biosimilar Enbrel) – FDA Advisory Committee Briefing Document Prepared by the FDA (July 13, 2016); www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM510493.pdf
  6. 6.
    FDA Drugs – Search Drugs@FDA – FDA Approved Drug Products: Nutropin (Somatropin): Approval History, Letters, Reviews and Related Documents – Package Insert (December 2016); www.accessdata.fda.gov/drugsatfda_docs/label/2016/019676s044,020168s024lbl.pdf
  7. 7.
    United States Pharmacopeia (USP-NF): General Chapters – <1084> Glycoprotein and Glycan Analysis – General Considerations; USP website, www.USP.org
  8. 8.
    FDA Advisory Committee Meetings – Meeting of the Oncology Drugs Advisory Committee: Mylan Ogivri (Trastuzumab, Biosimilar Herceptin) – FDA Advisory Committee Briefing Document Prepared by Mylan (July 13, 2017); www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566370.pdf
  9. 9.
    Beck, A., Wagner-Rousset, E., et.al., Characterization of Therapeutic Antibodies and Related Products; Anal. Chem. (2013) 85: 715–736CrossRefGoogle Scholar
  10. 10.
    FDA Advisory Committee Meetings – Meeting of the Oncology Drugs Advisory Committee: Mylan Ogivri (Trastuzumab, Biosimilar Herceptin) – FDA Advisory Committee Briefing Document Prepared by the FDA (July 13, 2017); www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566369.pdf
  11. 11.
    FDA Draft Guidance for Industry: Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up (July 2018); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610800.pdf
  12. 12.
    EMA European Public Assessment Report (EPAR): Imlygic (Talimogene Laherparepvec) (October 2015); www.ema.europa.eu/documents/assessment-report/imlygic-epar-public-assessment-report_en.pdf
  13. 13.
    EMA European Public Assessment Report (EPAR): Glybera (Alipogene Tiparvovec) (July 2012); www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002145/WC500135476.pdf
  14. 14.
    EMA Guideline on Quality, Non-Clinical and Clinical Aspects of Medicinal Products Containing Genetically Modified Cells (July 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252709.pdf
  15. 15.
    FDA Draft Guidance for Industry: Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs) (July 2018); www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM610795.pdf
  16. 16.
    EMA European Public Assessment Report (EPAR): Kymriah (Tisagenlecleucel) (June 2018); www.ema.europa.eu/documents/assessment-report/kymriah-epar-public-assessment-report_en.pdf
  17. 17.
    EMA European Public Assessment Report (EPAR): Yescarta (Axicabtagene Ciloleucel) (June 2018); www.ema.europa.eu/documents/assessment-report/yescarta-epar-public-assessment-report_en.pdf
  18. 18.
    FDA Vaccines, Blood & Biologics: Licensed Biologic Products with Supporting Data – Yescarta (Axicabtagene Ciloleucel) – Package Insert (2017); www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581226.pdf
  19. 19.
    FDA Guidance for Industry: CGMP For Phase 1 Investigational Drugs (July 2008); www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf
  20. 20.
    EMA Guideline on the Requirements For Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials (September 2018); www.ema.europa.eu/documents/scientific-guideline/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal_en-0.pdf
  21. 21.
    ICH M4Q(R1): Quality Overall Summary of Module 2, Module 3: Quality (September 2002); www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4_R1_Quality/M4Q__R1_.pdf
  22. 22.
    EMA Guideline on Development, Production, Characterization, and Specification for Monoclonal Antibodies and Related Products (July 2016): www.ema.europa.eu/documents/scientific-guideline/guideline-development-production-characterisation-specification-monoclonal-antibodies-related_en.pdf
  23. 23.
    EMA Guideline on the Quality, Non-Clinical and Clinical Aspects of Gene Therapy Medicinal Products (March 22, 2018); www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252056.pdf
  24. 24.
    FDA Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product (April 2015); www.fda.gov/downloads/drugs/guidances/ucm291134.pdf
  25. 25.
    EMA European Public Assessment Report (EPAR): Qarziba (Dinutuximab Beta Apeiron) (March 2017); www.ema.europa.eu/documents/assessment-report/dinutuximab-beta-apeiron-epar-public-assessment-report_en.pdf
  26. 26.
    EMA European Public Assessment Report (EPAR): Oxervate (Cenegermin, Recombinant Nerve Growth Factor) (May 2017); www.ema.europa.eu/documents/assessment-report/oxervate-epar-public-assessment-report_en.pdf

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • John Geigert
    • 1
  1. 1.BioPharmaceutical Quality SolutionsCarlsbadUSA

Personalised recommendations